150 related articles for article (PubMed ID: 15100321)
1. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice.
Tüzün E; Scott BG; Yang H; Wu B; Goluszko E; Guigneaux M; Higgs S; Christadoss P
J Immunol; 2004 May; 172(9):5743-52. PubMed ID: 15100321
[TBL] [Abstract][Full Text] [Related]
2. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptors and collagen induced arthritis in H-2r mice.
Griffiths MM; Cole BC; Ito J; Harper DS; Anderson GD; Cannon GW; Luthra HS; David CS
Autoimmunity; 1993; 14(3):221-9. PubMed ID: 8329559
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
5. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
Christadoss P; Tüzün E; Li J; Saini SS; Yang H
Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
[TBL] [Abstract][Full Text] [Related]
6. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody.
Tüzün E; Li J; Saini SS; Yang H; Christadoss P
J Neuroimmunol; 2007 Jan; 182(1-2):167-76. PubMed ID: 17137637
[TBL] [Abstract][Full Text] [Related]
7. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
8. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.
Deng C; Goluszko E; Tüzün E; Yang H; Christadoss P
J Immunol; 2002 Jul; 169(2):1077-83. PubMed ID: 12097416
[TBL] [Abstract][Full Text] [Related]
9. TCR gene usage in experimental autoimmune myasthenia gravis pathogenesis. Usage of multiple TCRBV genes in the H-2b strains.
Wu B; Shenoy M; Goluszko E; Kaul R; Christadoss P
J Immunol; 1995 Apr; 154(7):3603-10. PubMed ID: 7897239
[TBL] [Abstract][Full Text] [Related]
10. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.
Kaul R; Wu B; Goluszko E; Deng C; Dedhia V; Nabozny GH; David CS; Rimm IJ; Shenoy M; Haqqi TM; Christadoss P
J Immunol; 1997 Jun; 158(12):6006-12. PubMed ID: 9190955
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of Src homology 2 domain-containing protein tyrosine phosphatase 1 reduces T cell activation threshold but not the severity of experimental autoimmune myasthenia gravis.
Deng C; Wu B; Yang H; Hussain RZ; Lovett-Racke AE; Christadoss P; Racke MK
J Neuroimmunol; 2003 May; 138(1-2):76-82. PubMed ID: 12742656
[TBL] [Abstract][Full Text] [Related]
12. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. VI. Detection of a non-MHC gene(s) in the E alpha-bearing RIIIS mouse strain that is associated with a specific lack of T cell responses to the M. arthritidis soluble mitogen.
Cole BC; Tuller JW; Sullivan GJ
J Immunol; 1987 Aug; 139(3):927-35. PubMed ID: 3110289
[TBL] [Abstract][Full Text] [Related]
14. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
15. Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor.
Quintana FJ; Pitashny M; Cohen IR
Int Immunol; 2003 Jan; 15(1):11-6. PubMed ID: 12502721
[TBL] [Abstract][Full Text] [Related]
16. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis.
Yang B; McIntosh KR; Drachman DB
Clin Immunol Immunopathol; 1998 Jan; 86(1):45-58. PubMed ID: 9434796
[TBL] [Abstract][Full Text] [Related]
17. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
Deng C; Goluszko E; Christadoss P
J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
[TBL] [Abstract][Full Text] [Related]
18. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice.
Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA
J Immunol; 1992 Jun; 148(11):3385-90. PubMed ID: 1375242
[TBL] [Abstract][Full Text] [Related]
19. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
20. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.
Yang H; Tüzün E; Alagappan D; Yu X; Scott BG; Ischenko A; Christadoss P
J Immunol; 2005 Aug; 175(3):2018-25. PubMed ID: 16034147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
